A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination

Indian Journal of Medical Research

Volumn 131, Issue 5, 2010, Pages 670-674

  Motazedian, Shahdokht ^a   Babakhani, Lida ^a   Fereshtehnejad, Seyed Mohammad ^b   Mojtahedi, Khatereh ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bromocriptine; Cabergoline; Hyperprolactinemia; Infertility

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CHORIOMON; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; HUMAN MENOPAUSAL GONADOTROPIN; MERIONOL; PROLACTIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEMALE FERTILITY; FEMALE INFERTILITY; GALACTORRHEA; HEADACHE; HUMAN; HYPERPROLACTINEMIA; INTRAUTERINE INSEMINATION; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; NAUSEA; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; BROMOCRIPTINE; ERGOLINES; FEMALE; HUMANS; HYPERPROLACTINEMIA; INFERTILITY, FEMALE; INSEMINATION, ARTIFICIAL;

EID: 77952344321     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Josimovich JB, Lavenhar MA, Devanesan MM, Sesta HJ, Wilchins SA, Smith AC. Heterogeneous distribution of serum prolactin values in apparently healthy young women, and the effects of oral contraceptive medication. Fertil Steril 1987; 47: 785-91.
2. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocrine Rev 2006; 27: 485-534.
3. Serri O, Chik CL, Ur E, Ezzat Sh. Diagnosis and management of hyperprolactinemia. CMAJ 2003; 169: 575-81.
4. Verhelst J, Abstract R. Hyperprolactinemia: pathophysiology and management. Treat Endocrinol 2003; 2: 23-32.
5. Kleinberg DL, Boyd AE, Wardlaw S, Frantz AG, George A, Bryan N, et al. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med 1983;309: 704-9.
6. Webster J, Piscitelli G, Polli A, Ferrari C, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994; 331: 904-9.
7. Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 1999; 44: 1075-84.
8. Colao A, Abs R, Bárcena DG, Chanson P, Paulus W, Kleinberg DL. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf) 2008; 68: 66-71.
9. Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996; 10: 333-7.
10. Kiely J, Brett K, Yu S, Rowley D. In: Wilcox L, Marks J, editors. From data to action: CDC's public health surveillance for women, infants, and children. Atlanta: USDHHS, CDC; 1995. p. 185-202.
11. Enjalbert A, Backaert J. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. Mol Pharmacol 1983; 23: 576-84.
12. Besser GM, Parke L, Edwards CRW, Forsyth IA, MacNeilly AS. Galactorrhea: successful treatment with reduction of plasma prolactin levels. Br Med J 1972; 3: 669-72.
13. Vance ML, Evans WS, Thorner MO. Drugs five years later: bromocriptine. Ann Int Med 1984; 100: 78-91.
14. Ferrari C, Crosignani PG. Medical treatment of hyperprolactinemic disorders. Hum Reprod 1986; 1: 507-14.
15. Ferrari C, Barbieri C, Caldara R, Mucci M, Codecasa F, Paracchi A, et al. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 1986; 63: 941-5.
16. Mattei AM, Ferrari C, Baroldi P, Cabioni V, Paracchi A, Galparoli C, et al. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients. J Clin Endocrinol Metab 1988; 66: 193-8.
17. Ciccarelli E, Giusti M, Miola C, Potenzoni F, Sghedoni D, Camanni F, et al. Effectiveness and tolerability of long-term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab 1989; 69: 725-8.
18. Bille BMK, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, et al. Treatment of prolactinsecreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996; 81: 2338-43.